Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients
Open Access
- 11 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Pulmonary Medicine
- Vol. 20 (1), 1-6
- https://doi.org/10.1186/s12890-020-1172-4
Abstract
Fluoroquinolones (FQs) are potential drugs that inhibit DNA synthesis and are used in the treatment of multidrug-resistant tuberculosis (TB) and short-term anti-TB regimens. In recent years, a high proportion of FQ resistance has been observed in Mycobacterium tuberculosis isolates. The development of FQ resistance in multidrug-resistant TB negatively impacts patient treatment outcome and is a serious threat to control of TB. The study included a total of 562 samples from patients with pulmonary TB that had been on anti-tuberculosis therapy. MTBDRsl assays were performed for the molecular detection of mutations. Sequence analysis was performed for the characterization and mutational profiling of FQ-resistant isolates. FQ resistance was observed in 104 samples (18.5%), most of which were previously treated and treatment failure cases. A total of 102 isolates had mutations in DNA gyrase subunit A (gyrA), while mutations in gyrB were observed in only two isolates. Mutational analysis revealed that the mutations mostly alter codons 94 (replacing aspartic acid with glycine, D94G) and 90 (replacing alanine with valine, A90V). In MDR and treatment failure cases, resistance to FQs was most commonly associated with the D94G mutation. In contract, a high proportion of A90V mutations were observed in isolates that were newly diagnosed. The findings suggest that genotypic assays for FQ resistance should be carried out at the time of initial diagnosis, before starting treatment, in order to rule out mutations that impact the potential use of FQs in treatment and to control drug resistance.Keywords
Other Versions
This publication has 23 references indexed in Scilit:
- Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, IndiaJournal of Clinical Microbiology, 2016
- SpecificgyrAgene mutations predict poor treatment outcome in MDR-TBJournal of Antimicrobial Chemotherapy, 2015
- Diagnosis and Management of Latent Tuberculosis Infection: Table 1.Cold Spring Harbor Perspectives in Medicine, 2015
- Frequency and Geographic Distribution of gyrA and gyrB Mutations Associated with Fluoroquinolone Resistance in Clinical Mycobacterium Tuberculosis Isolates: A Systematic ReviewPLOS ONE, 2015
- Fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Pakistan 2010–2014: Implications for disease controlInternational Journal of Mycobacteriology, 2015
- Anti-tuberculosis drug resistance in Bangladesh: reflections from the first nationwide surveyThe International Journal of Tuberculosis and Lung Disease, 2015
- Characterization of Mutations Conferring Extensive Drug Resistance to Mycobacterium tuberculosis Isolates in PakistanAntimicrobial Agents and Chemotherapy, 2011
- Mechanisms of drug resistance in Mycobacterium tuberculosis.2009
- Fluoroquinolone Resistance in Mycobacterium tuberculosis and Mutations in gyrA and gyrBAntimicrobial Agents and Chemotherapy, 2009
- Evaluation of a New Line Probe Assay for Rapid Identification of gyrA Mutations in Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2005